Lilly claims another victory in Alimta patent defenceEli Lilly ended 2019 with a win in its long-running legal battle to prevent generics of its big-selling Share XLilly claims another victory in Alimta patent defencehttps://pharmaphorum.com/news/lilly-claims-another-victory-in-alimta-patent-defence/
Mylan up on OK for generic of Lilly’s $2bn cancer drug AlimtaShares in Mylan have risen after the FDA gave a tentative approval to its generic version of Eli Share XMylan up on OK for generic of Lilly’s $2bn cancer drug Alimtahttps://pharmaphorum.com/news/mylan-up-on-ok-for-generic-of-lillys-2bn-cancer-drug-alimta/
